reported these mutations in Ph+ ALL patients but with lower frequency compared to mutations in genes involved in transcriptional regulation and epigenetic modulation, namely FAT1, CRLF2, SF1, EP300, and CREBBP (all these genes are included in our panel except for FAT1). This evidence concerns the gene EP300 and acute lymphoblastic leukemia.